The aim of this proposal is to test strategies for gene therapy in vivo. This will be accomplished by engineering into the mouse genome mutations in the two major excitatory receptor systems in the mammalian brain which mediate fast synaptic transmission, the glutamate receptor and the cholinergic nicotinic receptor system. The glutamate receptor system mediates the vast majority of fast synaptic transmission in the mammalian brain and is implicated by many experiments in memory formation and neurodegenerative disease as is observed in Alzheimer~s patients. The cholinergic nicotinic receptor system has been implicated in memory function and the number of nicotinic receptors is dramatically reduced in Alzheimer~s disease. The hypothesis that a defect in the nicotinic receptor system contributes to the memory deficit observed in Alzheimer~s patients will be tested. Gene therapy strategies will then be attempted in the mutant mice to restore gene expression and cognitive function. The experiments will make use of recombinant DNA technology and the production of mutant mice by genetic engineering methods. Gene targeting methods will be used to knockout or disrupt glutamate receptor and nicotinic receptor genes in the adult mouse using the recently developed CRE/LoxP system. Mutations will be introduced into glutamate receptor genes which alter the glutamate receptors so that they flux abnormally high amounts of calcium into the cell during normal synaptic transmission. The mutant mice will be analyzed using a variety of techniques. The brains will be sectioned and examined for gross morphological changes and evidence of cell death. Behavioral tests including the Morris maze will be used to test for learning and memory function. After the mutant mice are characterized for neurodegenerative disease and cognitive deficits, attempts to cure the mutant mice will be carried out by expressing various potential ~protective~ or replacement proteins in the mouse brain using a number of different viral expression and cell graft systems.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG010435-11
Application #
6423828
Study Section
Project Start
2001-03-01
Project End
2002-08-31
Budget Start
Budget End
Support Year
11
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Salk Institute for Biological Studies
Department
Type
DUNS #
005436803
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Nagahara, Alan H; Wilson, Bayard R; Ivasyk, Iryna et al. (2018) MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates. Gene Ther 25:104-114
Chen, Zhijiang; Donnelly, Christopher R; Dominguez, Bertha et al. (2017) p75 Is Required for the Establishment of Postnatal Sensory Neuron Diversity by Potentiating Ret Signaling. Cell Rep 21:707-720
Hirai, Maretoshi; Arita, Yoh; McGlade, C Jane et al. (2017) Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. J Clin Invest 127:569-582
Overk, Cassia; Masliah, Eliezer (2017) Perspective on the calcium dyshomeostasis hypothesis in the pathogenesis of selective neuronal degeneration in animal models of Alzheimer's disease. Alzheimers Dement 13:183-185
Spencer, Brian; Desplats, Paula A; Overk, Cassia R et al. (2016) Reducing Endogenous ?-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. J Neurosci 36:7971-84
Xu, Jiqing; de Winter, Fred; Farrokhi, Catherine et al. (2016) Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model. Sci Rep 6:31692
Spencer, Brian; Potkar, Rewati; Metcalf, Jeff et al. (2016) Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease. J Biol Chem 291:1905-20
Wang, Ling; Conner, James M; Nagahara, Alan H et al. (2016) Rehabilitation drives enhancement of neuronal structure in functionally relevant neuronal subsets. Proc Natl Acad Sci U S A 113:2750-5
Valera, Elvira; Masliah, Eliezer (2016) Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord 31:225-34
Kratter, Ian H; Zahed, Hengameh; Lau, Alice et al. (2016) Serine 421 regulates mutant huntingtin toxicity and clearance in mice. J Clin Invest 126:3585-97

Showing the most recent 10 out of 183 publications